Skip to main content
main-content

GLP-1 receptor agonists


Browse the latest news, expert commentary, and educational content on the GLP-1 receptor agonist medication class.


Highlights

10-07-2021 | SGLT2 inhibitors | News

Real-world data back SGLT2 inhibitor benefits even for people initially free of CVD

A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.

06-29-2021 | ADA 2021 | Conference coverage | News

AMPLITUDE-O: Efpeglenatide offers cardiorenal protection in type 2 diabetes

Efpeglenatide provides significant cardiovascular and renal protection in people with type 2 diabetes at high risk for cardiorenal events, show the findings of the AMPLITUDE-O trial.

06-26-2021 | ADA 2021 | Conference coverage | News

Tirzepatide has efficacy edge over semaglutide in SURPASS-2

People with type 2 diabetes on metformin monotherapy have greater glycemic control improvement and weight reduction with tirzepatide than semaglutide, report the SURPASS-2 investigators.

More on GLP-1 receptor agonists

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits